MX345287B - Nuevas composiciones para tratar cmt y trastornos relacionados. - Google Patents

Nuevas composiciones para tratar cmt y trastornos relacionados.

Info

Publication number
MX345287B
MX345287B MX2011012817A MX2011012817A MX345287B MX 345287 B MX345287 B MX 345287B MX 2011012817 A MX2011012817 A MX 2011012817A MX 2011012817 A MX2011012817 A MX 2011012817A MX 345287 B MX345287 B MX 345287B
Authority
MX
Mexico
Prior art keywords
related disorders
new compositions
treating cmt
cmt
treating
Prior art date
Application number
MX2011012817A
Other languages
English (en)
Spanish (es)
Other versions
MX2011012817A (es
Inventor
Daniel Cohen
Iiya Chumakov
Serguei Nabirochkin
Original Assignee
Pharnext
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Pharnext filed Critical Pharnext
Publication of MX2011012817A publication Critical patent/MX2011012817A/es
Publication of MX345287B publication Critical patent/MX345287B/es

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/47—Quinolines; Isoquinolines
    • A61K31/485—Morphinan derivatives, e.g. morphine, codeine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/045—Hydroxy compounds, e.g. alcohols; Salts thereof, e.g. alcoholates
    • A61K31/047—Hydroxy compounds, e.g. alcohols; Salts thereof, e.g. alcoholates having two or more hydroxy groups, e.g. sorbitol
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/185—Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
    • A61K31/19—Carboxylic acids, e.g. valproic acid
    • A61K31/192—Carboxylic acids, e.g. valproic acid having aromatic groups, e.g. sulindac, 2-aryl-propionic acids, ethacrynic acid 
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/185—Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
    • A61K31/19—Carboxylic acids, e.g. valproic acid
    • A61K31/195—Carboxylic acids, e.g. valproic acid having an amino group
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/185—Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
    • A61K31/19—Carboxylic acids, e.g. valproic acid
    • A61K31/195—Carboxylic acids, e.g. valproic acid having an amino group
    • A61K31/197—Carboxylic acids, e.g. valproic acid having an amino group the amino and the carboxyl groups being attached to the same acyclic carbon chain, e.g. gamma-aminobutyric acid [GABA], beta-alanine, epsilon-aminocaproic acid or pantothenic acid
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/40—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil
    • A61K31/407—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil condensed with other heterocyclic ring systems, e.g. ketorolac, physostigmine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/4164—1,3-Diazoles
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/4164—1,3-Diazoles
    • A61K31/4178—1,3-Diazoles not condensed 1,3-diazoles and containing further heterocyclic rings, e.g. pilocarpine, nitrofurantoin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/4353—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems
    • A61K31/436—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems the heterocyclic ring system containing a six-membered ring having oxygen as a ring hetero atom, e.g. rapamycin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/439—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom the ring forming part of a bridged ring system, e.g. quinuclidine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/555—Heterocyclic compounds containing heavy metals, e.g. hemin, hematin, melarsoprol
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/56—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids
    • A61K31/565—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids not substituted in position 17 beta by a carbon atom, e.g. estrane, estradiol
    • A61K31/567—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids not substituted in position 17 beta by a carbon atom, e.g. estrane, estradiol substituted in position 17 alpha, e.g. mestranol, norethandrolone
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/56—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids
    • A61K31/575—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids substituted in position 17 beta by a chain of three or more carbon atoms, e.g. cholane, cholestane, ergosterol, sitosterol
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/70—Carbohydrates; Sugars; Derivatives thereof
    • A61K31/7004—Monosaccharides having only carbon, hydrogen and oxygen atoms
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0053—Mouth and digestive tract, i.e. intraoral and peroral administration
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/02—Drugs for disorders of the nervous system for peripheral neuropathies
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Chemical & Material Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Epidemiology (AREA)
  • Neurosurgery (AREA)
  • Neurology (AREA)
  • Biomedical Technology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • General Chemical & Material Sciences (AREA)
  • Emergency Medicine (AREA)
  • Molecular Biology (AREA)
  • Physiology (AREA)
  • Nutrition Science (AREA)
  • Psychiatry (AREA)
  • Hospice & Palliative Care (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Cosmetics (AREA)
  • Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
MX2011012817A 2009-06-02 2010-05-28 Nuevas composiciones para tratar cmt y trastornos relacionados. MX345287B (es)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
EP09305506A EP2263665A1 (fr) 2009-06-02 2009-06-02 Nouvelles compositions pour traiter le CMT et troubles associés
PCT/EP2010/057438 WO2010139627A1 (fr) 2009-06-02 2010-05-28 Nouvelles compositions pour le traitement du cmt et de troubles associés

Publications (2)

Publication Number Publication Date
MX2011012817A MX2011012817A (es) 2011-12-16
MX345287B true MX345287B (es) 2017-01-24

Family

ID=41168603

Family Applications (1)

Application Number Title Priority Date Filing Date
MX2011012817A MX345287B (es) 2009-06-02 2010-05-28 Nuevas composiciones para tratar cmt y trastornos relacionados.

Country Status (26)

Country Link
US (4) US20120088744A1 (fr)
EP (4) EP2263665A1 (fr)
JP (1) JP5875191B2 (fr)
KR (1) KR101740336B1 (fr)
CN (2) CN104688737B (fr)
AR (1) AR077540A1 (fr)
AU (1) AU2010255802B2 (fr)
BR (1) BRPI1013302B1 (fr)
CA (1) CA2763495C (fr)
CY (1) CY1115736T1 (fr)
DK (1) DK2437742T3 (fr)
EA (1) EA024523B1 (fr)
ES (2) ES2641191T3 (fr)
HK (2) HK1170150A1 (fr)
HR (1) HRP20141009T1 (fr)
IL (1) IL216621A (fr)
MX (1) MX345287B (fr)
NZ (1) NZ596656A (fr)
PL (1) PL2437742T3 (fr)
PT (1) PT2437742E (fr)
SG (1) SG176275A1 (fr)
SI (1) SI2437742T1 (fr)
SM (1) SMT201400160B (fr)
UA (1) UA110013C2 (fr)
WO (1) WO2010139627A1 (fr)
ZA (1) ZA201109423B (fr)

Families Citing this family (17)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP2065038A1 (fr) 2007-11-30 2009-06-03 Pharnext Nouvelles approches thérapeutiques pour traiter la maladie de Charcot-Marie-Tooth
EP2135607A1 (fr) 2008-06-18 2009-12-23 Pharnext Combinaison de pilocarpine et methimazol pour le traitement de la maladie de Charcot-MarieTooth et des troubles associés
EP2263665A1 (fr) 2009-06-02 2010-12-22 Pharnext Nouvelles compositions pour traiter le CMT et troubles associés
US9393241B2 (en) 2009-06-02 2016-07-19 Pharnext Compositions for treating CMT and related disorders
US9867837B2 (en) * 2011-03-01 2018-01-16 Pharnext Compositions for treating neurological disorders
ES2665569T3 (es) 2011-03-01 2018-04-26 Pharnext Tratamiento de la isquemia cerebral
US9248111B2 (en) 2011-03-01 2016-02-02 Pharnext Therapeutic approaches for treating parkinson's disease
US9931326B2 (en) 2011-03-29 2018-04-03 Pharnext Composition comprising torasemide and baclofen for treating neurological disorders
FR2987271B1 (fr) * 2012-02-28 2017-08-18 Hra Pharma Lab Combinaison de modulateurs selectifs du recepteur a la progesterone et d'anti-inflammatoires non steroidiens
WO2014163380A1 (fr) * 2013-04-02 2014-10-09 사회복지법인 삼성생명공익재단 Procédé de criblage d'agents thérapeutiques pour la maladie de charcot-marie-tooth et neurones moteurs auto-différenciés utilisés pour celui-ci
SG11201509824UA (en) * 2013-06-05 2015-12-30 Pharnext Stable oral solutions for combined api
RS56931B1 (sr) * 2013-12-13 2018-05-31 Pf Medicament Hromonski derivat kao antagonist dopaminskog d3 receptora za upotrebu u lečenju poremećaja autističnog spektra
MX2016010409A (es) 2014-02-11 2016-11-30 Pharnext Combinacion de baclofeno, acamprosato y trigliceridos de cadena media para el tratamiento de trastornos neurologicos.
EP3110411B1 (fr) * 2014-02-24 2019-11-06 Pharnext Nouvelles compositions pour traiter des lésions neuronales mécaniques
WO2016191241A1 (fr) * 2015-05-27 2016-12-01 Mmc & Company Llc Compositions pharmaceutiques à impact mitochondrial à cible double affectant l'état redox mitochondrial et procédés de traitement
US10383870B2 (en) 2016-06-10 2019-08-20 Pharnext Early treatment of CMT disease
CN111658643B (zh) * 2020-07-31 2021-12-07 西安交通大学医学院第一附属医院 雷帕霉素在难治性Graves病中的制药应用

Family Cites Families (32)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
TW427904B (en) * 1995-12-07 2001-04-01 American Home Prod Neuroprotective agents
CA2305179A1 (fr) * 1997-09-30 1999-04-08 Daiichi Pharmaceutical Co., Ltd. Preparation orale
EP1117425A2 (fr) 1998-10-02 2001-07-25 Celtrix Pharmaceuticals, Inc. Procedes pour traiter les troubles non thyroidiens
WO2002049607A2 (fr) 2000-12-20 2002-06-27 Firmenich Sa Systeme d'administration orale de medicament aromatise
JP3805646B2 (ja) * 2001-05-25 2006-08-02 久光メディカル株式会社 医薬液剤
CA2478558C (fr) 2002-03-14 2012-09-11 Euro-Celtique, S.A. Compositions a base de chlorhydrate de naltrexone
FR2842422B1 (fr) * 2002-07-16 2006-06-30 Univ Aix Marseille Ii Compositions destinees au traitement des neuropathies peripheriques, preparation et utilisations
CA2495917A1 (fr) 2002-08-28 2004-03-11 Merck Frosst Canada & Co. Derives de l'oxazolidin-2-one et de la thiazolidin-2-one antagonistes du recepteur ep4, pour le traitement du glaucome
CA2522471A1 (fr) 2003-04-14 2004-10-28 Pain Therapeutics, Inc. Procedes et materiaux de traitement des douleurs comprenant des antagonistes opioides
WO2004103263A2 (fr) 2003-05-22 2004-12-02 Yeda Research And Development Co. Ltd. Dopamine et ses agonistes et antagonistes permettant de traiter des maladies neurodegeneratives
ES2344350T3 (es) 2003-09-25 2010-08-25 Euro-Celtique S.A. Combinaciones farmaceuticas de hidrocodona y naltrexona.
US20050191343A1 (en) * 2003-11-26 2005-09-01 Shire Laboratories, Inc. Micellar systems useful for delivery of lipophilic or hydrophobic compounds
FR2865648B1 (fr) 2004-02-03 2006-06-30 Philippe Perovitch Procede de diffusion de molecules insolubles en milieu aqueux et composition mettant en oeuvre ce procede
US20050220863A1 (en) * 2004-04-02 2005-10-06 Chien-Hsuan Han Pharmaceutical dosage forms having controlled release properties that contain a GABAB receptor agonist
JP2006131545A (ja) 2004-11-05 2006-05-25 Japan Science & Technology Agency 神経因性疼痛治療剤
GB0509052D0 (en) * 2005-05-04 2005-06-08 Aimsco Ltd Combination therapy
US20070099947A1 (en) * 2005-11-03 2007-05-03 Alkermes, Inc. Methods and compositions for the treatment of brain reward system disorders by combination therapy
DE102006016990A1 (de) 2006-04-11 2007-10-18 Hermann, Holger Lars, Dr. Verwendung von Baclofen und Baclofen-Derivaten zur Entzugs- und/oder Substitutionsbehandlung bei Abhängigkeit von GHB und/oder GHB-Analogen
CA2651813A1 (fr) 2006-05-09 2007-11-22 Braincells, Inc. Neurogenese par modulation de l'angiotensine
WO2007134077A2 (fr) 2006-05-09 2007-11-22 Braincells, Inc. Neurogenèse induite par le récepteur 5ht
JP2010515754A (ja) 2007-01-11 2010-05-13 ゼノポート，インコーポレイティド Ｒ−バクロフェンのプロドラッグの徐放性経口剤形及び治療方法
US20080255062A1 (en) 2007-02-13 2008-10-16 University Of Manitoba Axon regeneration from adult sensory neurons
EP2065038A1 (fr) 2007-11-30 2009-06-03 Pharnext Nouvelles approches thérapeutiques pour traiter la maladie de Charcot-Marie-Tooth
EP2065821A1 (fr) 2007-11-30 2009-06-03 Pharnext Nouveau traitement médical pour empêcher l'association de drogues
EP2135607A1 (fr) * 2008-06-18 2009-12-23 Pharnext Combinaison de pilocarpine et methimazol pour le traitement de la maladie de Charcot-MarieTooth et des troubles associés
EP2263665A1 (fr) 2009-06-02 2010-12-22 Pharnext Nouvelles compositions pour traiter le CMT et troubles associés
US9393241B2 (en) 2009-06-02 2016-07-19 Pharnext Compositions for treating CMT and related disorders
EP2322163A1 (fr) 2009-11-03 2011-05-18 Pharnext Nouvelles approches thérapeutiques pour traiter la maladie d'Alzheimer
IT1400067B1 (it) 2010-05-21 2013-05-17 Molteni & C Spray nasale liquido contenente naltrexone a bassi dosaggi.
ES2665569T3 (es) 2011-03-01 2018-04-26 Pharnext Tratamiento de la isquemia cerebral
SG11201509824UA (en) 2013-06-05 2015-12-30 Pharnext Stable oral solutions for combined api
US10383870B2 (en) 2016-06-10 2019-08-20 Pharnext Early treatment of CMT disease

Also Published As

Publication number Publication date
EP2823817B1 (fr) 2017-06-21
CN104688737B (zh) 2019-11-08
CA2763495A1 (fr) 2010-12-09
MX2011012817A (es) 2011-12-16
BRPI1013302A2 (pt) 2018-01-09
UA110013C2 (uk) 2015-11-10
US10905686B2 (en) 2021-02-02
AR077540A1 (es) 2011-09-07
CY1115736T1 (el) 2017-01-25
ZA201109423B (en) 2012-09-26
JP2012528818A (ja) 2012-11-15
EP2263665A1 (fr) 2010-12-22
HK1206590A1 (en) 2016-01-15
CN102458387A (zh) 2012-05-16
HRP20141009T1 (hr) 2015-01-30
EA024523B1 (ru) 2016-09-30
US9427436B1 (en) 2016-08-30
CA2763495C (fr) 2018-06-26
EA201101686A1 (ru) 2012-06-29
PL2437742T3 (pl) 2015-03-31
EP2437742A1 (fr) 2012-04-11
NZ596656A (en) 2013-08-30
ES2641191T3 (es) 2017-11-08
US11672796B2 (en) 2023-06-13
US20160263104A1 (en) 2016-09-15
CN104688737A (zh) 2015-06-10
CN102458387B (zh) 2015-01-28
US20120088744A1 (en) 2012-04-12
AU2010255802A1 (en) 2011-12-22
DK2437742T3 (da) 2014-11-03
SMT201400160B (it) 2015-01-15
KR101740336B1 (ko) 2017-06-08
AU2010255802B2 (en) 2014-08-14
EP2823817A1 (fr) 2015-01-14
IL216621A (en) 2016-05-31
EP2437742B1 (fr) 2014-08-06
KR20120027353A (ko) 2012-03-21
JP5875191B2 (ja) 2016-03-02
WO2010139627A1 (fr) 2010-12-09
SG176275A1 (en) 2012-01-30
US20180250290A1 (en) 2018-09-06
BRPI1013302B1 (pt) 2022-07-12
IL216621A0 (en) 2012-02-29
ES2523268T3 (es) 2014-11-24
US20210322402A1 (en) 2021-10-21
SI2437742T1 (sl) 2015-02-27
EP3246025A1 (fr) 2017-11-22
PT2437742E (pt) 2014-11-04
HK1170150A1 (en) 2013-02-22

Similar Documents

Publication Publication Date Title
MX345287B (es) Nuevas composiciones para tratar cmt y trastornos relacionados.
EP2293800A4 (fr) Compositions et procédés pour le traitement de troubles de l'oreille
EP2440222A4 (fr) Compositions et méthodes pour prévenir et traiter des pathologies et des maladies cérébrales
MX2019011905A (es) Nuevas composiciones para el tratamiento de la esclerosis lateral amiotrofica.
MX2018009945A (es) Composiciones y metodos novedosos para el tratamiento de las enfermedades relacionadas con la inmunidad.
MX2011009690A (es) Métodos y composiciones para trastornos relacionados con la proliferación celurar.
MY163275A (en) Ibat inhibitors for the treatment of liver diseases
IN2012DN03883A (fr)
TR201819564T4 (tr) Cmt ve ilgili bozuklukların tedavisi için yeni terapötik yaklaşımlar.
IN2012DN00624A (fr)
MX353299B (es) Metodos y composiciones relacionadas con p62 para el tratamiento y profilaxis del cancer.
PT2300614E (pt) Métodos e composições para tratamento de distúrbios mitocondriais
EP2515926A4 (fr) Compositions et méthodes pour le traitement de maladies ophtalmiques liées à une angiogenèse
IL214455A0 (en) Methods and compositions for treatment of neovascularization
EP2490721A4 (fr) Compositions, procédés de traitement et de diagnostic de troubles liés à l'auto-immunité et procédé de fabrication de telles compositions
UA107666C2 (uk) Застосування l-серину як лікарського засобу для попередження та/або лікування свербіжу шкіри
MX2015003701A (es) Composiciones para tratamiento.
IL214745A0 (en) Treatment of insulin-resistant disorders
EP2675275A4 (fr) Compositions et méthodes utilisables en vue du traitement de l'obésité et des troubles associés
EP4070794A3 (fr) Procédés d'utilisation de dérivés d'amides cycliques destinés à traiter des troubles induits par le récepteur sigma
MX2012007142A (es) Uso de 2,3-dihidroxipropil dodecanoato para tratar seborrea.
PL2375912T3 (pl) Kompozycje i sposoby leczenia uczucia dyskomfortu gardła
HU0900231D0 (en) Compositions for the treatment of allergic disorders
MX2011013324A (es) Uso de derivados de oxindol sustituidos para el tratamiento y profilaxis del dolor.
MX2011012140A (es) Ranolazina para el tratamiento de problemas del snc.

Legal Events

Date Code Title Description
FG Grant or registration